FCM
HZNP

Flinton Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Flinton Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$47K Buy
+1,728
New +$44.7K ﹤0.01% 827

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Flinton Capital Management's HZNP Position: Q3 2019 in Review

Flinton Capital Management opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2019: 1,728 shares worth $47K. The stake represents ﹤0.01% of the portfolio and ranks #827 among its holdings.

264 funds tracked by Wall St. Rank hold HZNP as of Q3 2019.

  • Flinton Capital Management held 1,728 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $47K as of Q3 2019.
  • Horizon Therapeutics Public Limited Company Ordinary Shares was a new Flinton Capital Management position in Q3 2019.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #827 holding.
  • 264 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.